AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00826774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling
Description: These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
Study NCT00458900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV and enteral administration of moxifloxacin
Description: IV and enteral administration of moxifloxacin
Study NCT01135641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
Study NCT01135641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporine
Study NCT01135641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Study NCT04590443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study NCT00650000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Tablets 200 mg
Description: 200mg, single dose fasting
Study NCT00650000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provigil® Tablets 200 mg
Description: 200mg, single dose fasting
Study NCT00406848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
Study NCT00406848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
Study NCT00583700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
Study NCT00583700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E (Over-the-counter) 400 I.U. once daily
Study NCT00930488 — intervention group
Intervention type: DRUG
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Study NCT05282160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epino
Description: The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
Study NCT00977106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: single iv infusion 8 mg/kg
Study NCT00977106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single iv infusion
Study NCT00977106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: iv infusion 8mg/kg every 4 weeks for 11 months
Study NCT01522352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement by bioprosthesis
Description: Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
Study NCT03231670 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: 5ml blood will be taken in addition to standard sampling
Study NCT01894178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker Flex-Tip® tracheal tube
Study NCT01894178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portex® Tracheal Tube
Study NCT01720082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic appendectomy
Description: A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
Study NCT01720082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiport laparoscopic appendectomy
Description: Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
Study NCT01179880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005
Description: Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
Study NCT01179880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for each step
Study NCT03030066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1001b
Description: Generic not assigned
Study NCT04182737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgM-enriched polyclonal immunoglobulins titer-based treatment
Description: Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
Study NCT04182737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IgM-enriched polyclonal immunoglobulins Flat treatment
Description: Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
Study NCT00256672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam
Description: TLSO back brace, Flex-Foam (Posterior Opening)
Study NCT04149756 — intervention group
Intervention type: OTHER
Intervention: observation of weight after 6months
Description: This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. .
Study NCT02747745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four risk areas reflecting the great needs of FCGs of PWDs
Description: The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
Study NCT00175357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
Study NCT00175357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamorphine hydrochloride
Description: The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
Study NCT02010762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 25.000 IU oral drops
Study NCT02010762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral drops
Study NCT04647604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven®
Description: A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
Study NCT04647604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: intravenously administered 2 mL/kg/day
Study NCT01955590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: 8-12 sessions of manualized metacognitive therapy
Study NCT01955590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: 8-12 sessions of manualized EMDR
Study NCT01955590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: 8-12 sessions of treatment of usual
Study NCT02695732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
Study NCT02695732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy
Description: Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
Study NCT02597543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.
Study NCT02597543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For use in both perfusion imaging and late gadolinium enhancement.
Study NCT02597543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
Study NCT04686253 — intervention group
Intervention type: OTHER
Intervention: not appliable
Description: not appliable
Study NCT03655106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Long IV 4.78 cm 20 g catheter
Description: Standard Long IV 4.78 cm 20 g catheter
Study NCT03655106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-Long IV 6.35 cm 20 g catheter
Description: Ultra-Long IV 6.35 cm 20 g catheter
Study NCT00508170 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
Study NCT01718639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-LH-101 tablet
Description: Oral medical device in the form of a chewable tablet
Study NCT01718639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-LH-101 liquid
Description: Oral medical device in the form of a liquid
Study NCT01718639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02684682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (12h)
Description: Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
Study NCT01791712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Description: pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
Study NCT01791712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux Hemodialysis
Description: blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
Study NCT02684682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (24h)
Description: Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
Study NCT02684682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (48h)
Description: Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
Study NCT03377881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI/Fusion biopsies
Description: The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.
Study NCT03377881 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Systematic biopsies
Description: The intervention in the control arm is traditional systematic biopsies of the prostate.
Study NCT04240938 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dacryocystorhinostomy
Description: Anastomosis between lacrimal sac and nasal cavity
Study NCT01303978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: Single dose
Study NCT02710201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive Social Norm
Study NCT02710201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive-plus-Injunctive Social Norm
Study NCT04281706 — intervention group
Intervention type: DRUG
Intervention: Etomidate vs Propofol as induction agent
Description: Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
Study NCT01935440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention & Testing
Description: 6 group sessions, 1 individual session, and 1 dyad session
Study NCT01935440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention & Testing Control
Description: 7 group sessions
Study NCT02924948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Description: EUS balloon inflation will be done before insertion through the subjects throat
Study NCT00357448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
Study NCT00357448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal administration
Description: After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
Study NCT00357448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00357448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT00357448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT03220867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Xian Risperdal (test)
Description: Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.
Study NCT03220867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Gurabo Risperdal (reference)
Description: Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
Study NCT01424722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices
Description: Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
Study NCT01485965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg, immediate release tablets, once daily administration
Study NCT03680898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal swab collection
Description: Patient will provide a rectal swab by following hospital-provided instructions.
Study NCT03680898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal swab collection
Description: Patient will provide a rectal swab by following hospital-provided instructions.
Study NCT04449484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Intravenous infusion over 60 minutes
Study NCT04449484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion over 60 minutes
Study NCT00864864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
Study NCT03252470 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-y Gastric Bypass Surgery
Description: Laparoscopic Roux-en-y Gastric Bypass Surgery
Study NCT01418157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 125 mg twice daily until 4380 meters altitude
Study NCT01418157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study NCT02391064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: * Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test
Study NCT02391064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS) score
Description: - EDSS score
Study NCT01192646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBLSS
Description: Home Based life saving skills training will be done in the intervention cluster while in the control group no training
Study NCT01192646 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: HBLSS
Description: Home Based life saving skills training will be done in the intervention cluster while in the control group no training
Study NCT01307098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 0.35 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study NCT01307098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 1 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study NCT01307098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 3 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study NCT00995410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
Study NCT02048865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 2.5 mg tablets BID for 6 months
Study NCT02048865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: placebo drug 2.5mg BID for 6 months
Study NCT01453075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir 1.5 mg po bid
Study NCT01453075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo twice daily